Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Diabetes Type 2, Bariatric Surgery
Phase NA
Enrollment 5
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

English, Hindi and Gujarati

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Magnetic Compression Anastomosis Procedure for Partial Jejuno-ileal Diversion — This is an Investigator Initiated, prospective, single-center, single-arm observational study evaluating feasibility and safety of novel magnetic compression Anastomosis device on the formation of partial jejunoileal diversion among obese patients with Type II Diabetes Mellitus (T2DM). A total of 5 patients will be recruited in the study. Following the administration of general anesthesia, an upper GI endoscope (iIDEAs EMMIT System) with the magnet will be maneuvered to the proximal jejunum. Following this, the snare catheter will release the distal magnet at the designated location, which is approximately 20 cm (± 10 cm) distal to the ligament of Treitz. Concurrently, the lower GI endoscope will be inserted into the terminal ileum through the ileocecal valve. The snare catheter will then assist in positioning the second magnet at the target area, located approximately 20 cm (± 10 cm) proximal to the ileocecal valve. Laparoscopic techniques will be employed

Primary Outcomes

  • Magnetic Compression Anastomosis Procedure for Partial Jejuno-ileal Diversion: Evaluating the Feasibility of a Novel Endoscopic Magnetic Metabolic Interventional Therapy (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-11
Completion: 2026-11-30
Eligibility
Age: 25 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 5 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: iIDEAS Group Holdings Limited
Contact Information
Study Contact:
Purvi Chavda, MD
8905818034
purvi@curexbio.com
Purvi A Chavda, MD
08905818034
purvi@curexbio.com
AB Plus Speciality Hospital
Interventions
  • Device: Magnetic Compression Anastomosis Procedure for Partial Jejuno-ileal Diversion — This is an Investigator Initiated, prospective, single-center, single-arm observational study evaluating feasibility and safety of novel magnetic compression Anastomosis device on the formation of partial jejunoileal diversion among obese patients with Type II Diabetes Mellitus (T2DM). A total of 5 patients will be recruited in the study. Following the administration of general anesthesia, an upper GI endoscope (iIDEAs EMMIT System) with the magnet will be maneuvered to the proximal jejunum. Following this, the snare catheter will release the distal magnet at the designated location, which is approximately 20 cm (± 10 cm) distal to the ligament of Treitz. Concurrently, the lower GI endoscope will be inserted into the terminal ileum through the ileocecal valve. The snare catheter will then assist in positioning the second magnet at the target area, located approximately 20 cm (± 10 cm) proximal to the ileocecal valve. Laparoscopic techniques will be employed
Study Locations (1 sites)
AB Plus Speciality Hospital, Ahmedabad, Gujarat 380054 India
Eligibility Criteria
Inclusion Criteria: 1. Participants are willing and able to give informed consent for participation in the study. 2. Male or Female, aged ≥ 25 years to ≤ 65 years inclusive at the time of informed consent 3. BMI 30-50 * Prior sleeve gastrectomy (\> 12 months) or other metabolic surgical procedures with T2DM (characterized by HbA1c \> 6.5%) or weight regain * T2DM without a history of gastrectomy or other metabolic surgical procedures (diagnosis for \> 6M and \<10 yrs) taking at least oral antidiabetic medication with fasting glucose \< 200mg/dl and HbA1c \>6.5 % 4. Agrees to abstain from any form of additional bariatric or reconstructive surgery that could influence body weight for a duration of 1 year Exclusion Criteria: 1. Pregnancy or breastfeeding mothers, or individuals planning to become pregnant in next 9-12 months 2. Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.) 3. Current enrolment in another research study or previous participation within 30 days of enrolment 4. Use of injectable insulin 5. Uncontrolled T2DM 6. Uncontrolled hypertension, dyslipidemia, or sleep apnea 7. Current history of injected Glucagon Like Peptide 1 (GLP1) 8. Evidence of type 1 diabetes or of pancreatic exhaustion, as indicated by a C peptide fasting level less than 1 or, for type 1 diabetes, based on measurable levels of serum anti-GAD-65 autoantibodies or, at investigator's discretion, based on measurable levels of other T1D-associated autoantibodies 9. History of highly unusual or challenging gastrointestinal tract anatomy ascertained through earlier endoscopic examination or other diagnostic imaging 10. Previous intestinal, colonic, or duodenal surgery, excluding bariatric procedures 11. Prior surgical interventions, trauma, prosthetic implants, diseases, or genetic factors that hinder or contraindicate the procedure, including scarring and abnormal anatomical structures 12. History of (or known to be at prohibitive risk for) any of the following diseases of the small bowel or closely related conditions: Crohn's disease or other inflammatory bowel disease, celiac disease, resection for cancer, or intra-abdominal adhesive disease including intussusception, perforated appendix and Meckel's diverticulum 13. Refractory gastroesophageal reflux disease (GERD) 14. Barrett's esophagus 15. Any anatomical anomaly that obstructs orogastric access via gastroscope and catheters, as well as manipulation techniques 16. Presence of an implantable pacemaker or defibrillator 17. Any comorbidity or current physiological condition of the subject that, in the opinion of the surgeon or anesthesiologist, poses safety concerns rendering the subject medically unfit for the procedure. This encompasses any conditions for which endoscopic or laparoscopic surgery would be contraindicated, as well as any significant congenital or acquired anomalies of the gastrointestinal tract at or distal to the magnet placement site Subjects will be deemed ineligible to participate if they fulfill any of the following criteria: 1\. Pregnancy or breastfeeding mothers, or individuals planning to become pregnant in next 9-12 months 2. Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.) 3. Current enrolment in another research study or previous participation within 30 days of enrolment 4. Use of injectable insulin 5. Uncontrolled T2DM 6. Uncontrolled hypertension, dyslipidemia, or sleep apnea 7. Current history of injected Glucagon Like Peptide 1 (GLP1) 8. Evidence of type 1 diabetes or of pancreatic exhaustion, as indicated by a C peptide fasting level less than 1 or, for type 1 diabetes, based on measurable levels of serum anti-GAD-65 autoantibodies or, at investigator's discretion, based on measurable levels of other T1D-associated autoantibodies 9. History of highly unusual or challenging gastrointestinal tract anatomy ascertained through earlier endoscopic examination or other diagnostic imaging 10. Previous intestinal, colonic, or duodenal surgery, excluding bariatric procedures 11. Prior surgical interventions, trauma, prosthetic implants, diseases, or genetic factors that hinder or contraindicate the procedure, including scarring and abnormal anatomical structures 12. History of (or known to be at prohibitive risk for) any of the following diseases of the small bowel or closely related conditions: Crohn's disease or other inflammatory bowel disease, celiac disease, resection for cancer, or intra-abdominal adhesive disease including intussusception, perforated appendix and Meckel's diverticulum 13. Refractory gastroesophageal reflux disease (GERD) 14. Barrett's esophagus 15. Any anatomical anomaly that obstructs orogastric access via gastroscope and catheters, as well as manipulation techniques 16. Presence of an implantable pacemaker or defibrillator 17. Any comorbidity or current physiological condition of the subject that, in the opinion of the surgeon or anesthesiologist, poses safety concerns rendering the subject medically unfit for the procedure. This encompasses any conditions for which endoscopic or laparoscopic surgery would be contraindicated, as well as any significant congenital or acquired anomalies of the gastrointestinal tract at or distal to the magnet placement site 18. History of small bowel surgery such as small bowel resection 19. Active H. pylori infection (prospective participants with active H. pylori may continue with the screening process if they are treated via medication and re-testing verifies the condition has resolved.) 20. History of chronic or acute pancreatitis 21. Known active hepatitis or active liver disease 22. Symptomatic gallstones or kidney stones or acute cholecystitis 23. History of coagulopathy, upper gastro-intestinal bleeding conditions such as ulcers, gastric varices, strictures, congenital or acquired intestinal telangiectasia 24. Use of anticoagulation therapy (excluding aspirin) which cannot be discontinued for 7 days before and 14 days after the procedure 25. Use of P2Y12 inhibitors (clopidogrel, pasugrel, ticagrelor) which cannot be discontinued for 14 days before and 14 days after the procedure (use of low-dose aspirin allowable) 26. History of serious complications of T2DM including coronary artery disease, hypertension, peripheral vascular disease, diabetic retinopathy, and/or diabetes-related soft tissue infection 27. Taking corticosteroids or drugs known to affect GI motility (e.g. Metoclopramide) 28. Receiving weight loss medications such as Meridia, Xenical, or over-the-counter weight loss medications 29. Persistent anemia, defined as Hgb\<10 g dL-1 30. Estimated Glomerular Filtration Rate (eGFR) or Modified of Diet in Renal Disease (MDRD) \<30 ml/min/1.73m2 31. Active systemic infection 32. Chemotherapeutic cancer treatment within past 9 months, history of abdominal radiation, or active malignancy within the past 5 years 33. Active illicit substance abuse or alcoholism 34. Unhealed ulcers, bleeding lesions, tumors, or any other lesions at the target site for magnet deployment 35. Anticipated requirement for MR imaging within the first two months following the procedure 36. Any anatomical anomaly that prevents or contraindicates laparoscopic access and general laparoscopic procedures 37. Underwent a surgical or interventional procedure within 30 days prior to the current procedure 38. Any scheduled surgical or interventional procedure planned within 30 days following the current procedure 39. Any stroke or transient ischemic attack (TIA) within six months prior to obtaining consent 40. Any other serological markers likely to be associated with poor outcomes 41. Inability to adhere to the follow-up schedule and assessments 42. Any circumstance that, according to the investigator's judgment, could hinder the completion of follow-up evaluations up to Day 360 (for instance, a health issue that might elevate the risks linked to study involvement or could obstruct the analysis of
Conditions Mitochondrial Diseases, Maternally Inher...
Phase PHASE3
Enrollment 220
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

The KHENERFIN study aims to determine whether the study medicine, sonlicromanol, is able to reduce symptoms of fatigue and the impact of fatigue on daily life, and whether sonlicromanol is able to improve physical abilities of people like balance control and lower limb skeletal muscle strength in people with mitochondrial disease. In this study, the effects of sonlicromanol are compared against a placebo, a tablet identical in appearance and taste but without the active drug. Participants take either sonlicromanol or placebo twice daily for a treatment duration of 52 weeks. In addition to these primary objectives, the study evaluates the efficacy of sonlicromanol on secondary and exploratory outcomes, as well as its safety and tolerability after one year of treatment.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Sonlicromanol — Administration of 90 mg sonlicromanol (100 mg sonlicromanol.HCl) twice daily during 52 weeks
  • Drug: Placebo — Administration of 100 mg placebo twice daily during 52 weeks

Primary Outcomes

  • Neuro-QoL Fatigue Short Form v1 (Screening, Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit))
  • Five Times Sit-To-Stand Test (5XSST) (Screening, Baseline (Day 1), Weeks 13, 26, 39, 52 (End of Trial Visit))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-04-14
Completion: 2029-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Khondrion BV
Contact Information
Study Contact:
Jasper Levink, MSc.
+31 24 7635000
Khenerfin@khondrion.com
G. Ruiterkamp, MSc.
+31 24 7635000
Khenerfin@khondrion.com
Erica Kelly
617-724-7726
elkelly@mgh.harvard.edu
Massachusetts General Hospital
Interventions
  • Drug: Sonlicromanol — Administration of 90 mg sonlicromanol (100 mg sonlicromanol.HCl) twice daily during 52 weeks
  • Drug: Placebo — Administration of 100 mg placebo twice daily during 52 weeks
Study Locations (10 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Cleveland Clinic Neurological Institute Mellen Center, Cleveland, Ohio 44195 United States
The University of Texas Health Science Center at Houston, Houston, Texas 77030 United States
Rigshospitalet, University of Copenhagen, Kopenhagen, Region Sjælland DK2100 Denmark
CHU de Bordeaux - Hôpital Pellegrin Service Gynecologie Obstetrique, Bordeaux, Gironde 33000 France
Groupe Hospitalier Pitie-Salpetriere - Charles-Foix Clinical Investigation Center Paris-Est, Paris, Paris 75013 France
Klinikum der Universität München Friedrich-Baur-Institut, München, 80336 Germany
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, 20133 Italy
Radboud University Medical Center, Nijmegen, Gelderland 6525 Netherlands
University College London Hospitals NHS Foundation Trust National Hospital for Neurology and Neurosurgery, London, Greater London WC1N 3BG United Kingdom
Eligibility Criteria
Inclusion criteria 1. Signed Informed Consent 2. Males and females aged ≥18 years with a multi-system primary mitochondrial disease. 3. A confirmed mitochondrial DNA tRNALeu(UUR) m.3243A\>G mutation (m.3243A\>G PMD) plus an age adjusted heteroplasmy percentage ≥ 20% in white blood cells \[=blood heteroplasmy/0.977(age+12)\]. Or in urine (urinary epithelial cells), or buccal smear or skeletal muscle (results (obtained per local guidance) ≥ 20% must be available prior to the subject being randomized). 4. Presence of chronic fatigue (not attributable to other etiologies than PMD): 1. Patient self-reported chronic fatigue for at least 3 months prior to the Screening Visit and recorded in the clinical patient files; AND 2. Presence of fatigue (raw total score \>22), assessed by Neuro-QoL SFv1-F at Screening. 5. Presence of mitochondrial myopathy defined as: 5xSST at Screening and Baseline should be ≥ 11 seconds and participant must demonstrate the ability to complete the test at baseline (i.e., complete the test within 30 seconds). 6\. Other Inclusion criteria per protocol. Exclusion criteria 1. Treatment with any IMP within 3 months (or 5 times the half-life of the IMP, whichever is longer) prior to screening or plans to use an IMP (other than the study intervention) during the study. 2. Bone deformities, motor abnormalities or chronic ulcers that in the opinion of the PI may interfere with and/or confound the interpretation of the subject's performance during the 5 times sit to stand test (5XSST). 3. Surgery of gastrointestinal tract that might interfere with drug absorption. Or severe GI dysmotility, chronic vomiting, diarrhea, bouts of pseudo-obstruction which will impair appropriate IMP absorption in the opinion of the investigator. 4. Clinically significant respiratory disease and/or cardiac disease (medical history or current clinical findings) in the opinion of the investigator. 5. Prior interventional cardiac procedure (e.g., cardiac catheterization, angioplasty/percutaneous coronary intervention, balloon valvuloplasty, etc.) within 3 months prior to screening. 6. Structural heart disease based on cardiac MRI or Echocardiography (e.g., clinically significant valve disease; i.e., aortic or mitral valve stenosis or regurgitation) and / or Left ventricular dysfunction (LVEF \<52% in men and \< 54% in women) and / or congestive cardiac failure (more severe than grade II) and / or Maximum left-ventricular septal or posterior wall thickness \> 15 mm and / or Evidence of active myocardial ischaemia, ECG evidence and / or recent history of myocardial infarction (\< 6-months) and / or coronary angioplasty / coronary bypass surgery (\< 12 months). 7. Family history of unexplained/uninvestigated syncope or congenital long and short QT syndrome or sudden death (under the age of 60) and / or Abnormal QTcF interval \[QTcF \> 450 msec (men) or QTcF \> 470 msec (women) = abnormally long QTcF or QTcF \< QT \< 320ms = abnormally short QtcF\] and / or Intermittent or persistent WPW (pre-excitation) syndrome on ECG \[ie: abnormally wide QRS \> 120ms with slurred up-stroke ('delta' wave) and PR-interval \< 120ms\] and / or ECG evidence of atrial fibrillation (permanent, persistent or paroxysmal) and / or High grade AV Block \[2nd-degree AV block Type II (ie: 2:1) or complete AV block (3rd degree) or intermittent conduction system abnormalities with the exception of any of the following: * 1st degree atrioventricular (AV)-block * 2nd degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type) * Right bundle branch block. 8. History of acute heart failure (within the last 3 months). 9. Higher degree of AV-blocks (AVB II° or III°). 10. Other exclusion criteria per protocol
Conditions Bariatric Surgery Candidate, Diabetes
Phase NA
Enrollment 408
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

Bariatric surgery procedures induce weight loss through restriction and/or malabsorption. The mechanisms underlying type 2 diabetes remission and others metabolic improvements after Roux-en-Y Gastric Bypass (RYGB), sleeve gastrectomy (SG) or biliopancreatic diversion with duodenal switch (BPD-DS) have not yet been formally studied. The investigators propose a longitudinal study with the overall objective of measuring the long-term impact of these three bariatric surgeries (RYGB, SG, BPD-DS) on metabolic, renal and cardiovascular fate in patients with type 2 diabetes. The investigators overall hypothesis is that some bariatric procedures generate hitherto unrecognized effects on many disease-related outcomes, which greatly contributes to their beneficial impact in diabetic patients. The investigators propose 3 specific aims: 1) to establish the long term effect of the three surgeries on the metabolic recovery and quality of life in groups of diabetic patients treated with insulin, hypoglycemic agents or diet; 2) to establish the long term impact of the three surgeries on renal and cardiovascular functions in subgroup of patients with these conditions; 3) to compare metabolic impact of surgeries to those of best medical care for diabetes in a non-surgical control group. For most severely obese patients, lifestyle interventions, perhaps effective in inducing short-lived weight losses, are ineffective for long-term weight loss maintenance and durable metabolic recovery. The increasing popularity of obesity surgeries calls for a better understanding of the underlying mechanisms. This is especially true and urgent when considering that knowledge on the relative impact of each procedure (i.e. SG vs. RYGB and BPD-DS) in resolving T2D is still limited. Better knowledge on each of the procedures will allow stronger scientific rationale for selecting the right surgery for the right patient and improve care for the severely obese individual.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Sleeve Gastrectomy
  • Procedure: Roux-en-Y Gastric Bypass
  • Procedure: Biliopancreatic Diversion with Duodenal Switch
  • Other: Medical management

Primary Outcomes

  • Type 2 diabetes remission rate (from baseline up to 60 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2015-03
Completion: 2030-03
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 408 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Laval University
Collaborators: Johnson & Johnson K.K. Medical Company, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Contact Information
Study Contact:
Melanie Nadeau, MSc
418-656-8711
melanie.nadeau@criucpq.ulaval.ca
Melanie Nadeau, MSc
418-565-8711
melanie.nadeau@criucpq.ulaval.ca
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Suzy Laroche
418-656-8711
suzy_laroche@ssss.gouv.qc.ca
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Interventions
  • Procedure: Sleeve Gastrectomy
  • Procedure: Roux-en-Y Gastric Bypass
  • Procedure: Biliopancreatic Diversion with Duodenal Switch
  • Other: Medical management
Study Locations (1 sites)
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Quebec G1V 4G5 Canada
Eligibility Criteria
Inclusion Criteria: * BMI ≥ 35 * type 2 diabetes * HbA1c ≥ 6,5 % or fasting glycemia ≥7mmol/l or non-fasting glycemia ≥11mmol/l * able to consent Exclusion Criteria: * pregnancy * past esophageal, gastric or bariatric surgery * irritable bowel, unexplained intermittent vomiting, severe abdominal pain, chronic diarrhea or constipation * history of gastric or duodenal ulcers * pre-operatory hypoalbuminemy * history of renal, hepatic, cardiac or pulmonary severe disease * taken of corticosteroid in the last month * evidence of psycological problem that may affect the capacity to understand the project and to comply with the medical recommandations * history of drug use or alcool abuse in the last 12 months * history of gastro-intestinal inflammatory diseases
Conditions Type 2 Diabetes
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

People with newly diagnosed type 2 diabetes treated with metformin that have not reached their HbA1c target (42-64 mmol/mol) will be recruited to the study. If they fulfill the inclusion and none of the exclusion criteria, they will be, after signing informed consent, randomized to a six-month intervention with either pioglitazone, empagliflozin or semaglutide. Fat biopsies are obtained from the subcutaneous abdominal area before and after a hyperinsulinemic-euglycemic clamp at baseline and after six months. Participants are regularly followed during this the intervention. The overall goal is to determine how antidiabetic-drugs affect white adipose tissue cellularity and whether adipose heterogeneity impacts on drug response. The primary outcome measure is the change in fat tissue lipolysis (glycerol release in isolated fat cells after hormone stimulation) before and after treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pioglitazone 45 mg — Starts with 45 mg
  • Drug: Empagliflozin 25 MG — Starts with 25 mg
  • Drug: Semaglutide 7 MG — Starts with 3 mg daily for the first 2 weeks

Primary Outcomes

  • Changes in fat cell lipolysis after 6 months of treatment (Baseline and after six months intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-02-08
Completion: 2032-12-31
Eligibility
Age: 30 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Karolinska Institutet
Collaborators: Karolinska University Hospital
Contact Information
Study Contact:
Mikael Ryden, MD, PhD
+46736995215
mikael.ryden@ki.se
Jesper Bäckdahl, MD, PhD
+46702297237
jesper.backdahl@ki.se
Mikael Rydén, MD, PhD
0736995215
mikael.ryden@ki.se
Karolinska University Hospital
Interventions
  • Drug: Pioglitazone 45 mg — Starts with 45 mg
  • Drug: Empagliflozin 25 MG — Starts with 25 mg
  • Drug: Semaglutide 7 MG — Starts with 3 mg daily for the first 2 weeks
Study Locations (1 sites)
Karolinska University Hospital, Stockholm, 14186 Sweden
Eligibility Criteria
Inclusion Criteria: * Signed informed consent * BMI 25 kg/m2 or higher * HbA1c 42 mmol/mol or higher * For fertile women, effective contraception Exclusion Criteria: * HbA1c 65 mmol/mol or higher * Established cardiovascular disease and/or heart failure * Severe psychiatric condition * Active alcoholism * Insulin treatment * Anticoagulant therapy (vitamin K antagonists or equivalent) * Pregnancy, lactation * Positive GAD or IA2 antibodies * Low C-peptide/glucose ratio (less than 2 measured as pmol/mg per dL) * NT-proBNP above the upper normal reference value * Kidney disease * Liver disease or hepatic values over twice the upper reference value * Severe concomitant disease including ongoing cancer
Conditions Type 2 Diabetes
Phase NA
Enrollment 102
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This is a single-arm pragmatic clinical trial of time-restricted eating in patients with type 2 diabetes. Patients will be recruited from the University of Kentucky Barnstable Brown Diabetes Center. Subjects will participate in a 10-hour time-restricted eating intervention for 1-year.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Time-restricted eating — Subjects will consume all daily calories within a 10-hour (10h +/- 1hr) window during the daytime, ending by 8:00pm. Subjects will text the time of their first and last daily calorie intake for the duration of the study.

Primary Outcomes

  • Change in Hemoglobin A1c (At least 2 timepoints between baseline and 1 year. Since labs will depend on clinic visits, exact timeframe will vary.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-20
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 102 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Justin (Matt) Thomas
Collaborators: University of Kentucky Barnstable Brown Diabetes and Obesity Center
Principal Investigators:
  • Matt Thomas, PhD (PRINCIPAL_INVESTIGATOR) - University of Kentucky
Contact Information
Study Contact:
Matt Thomas, PhD
859-562-0642
MattThomas@uky.edu
Matt Thomas, PhD
859-562-0642
MattThomas@uky.edu
University of Kentucky Barnstable Brown Diabetes Center
Interventions
  • Behavioral: Time-restricted eating — Subjects will consume all daily calories within a 10-hour (10h +/- 1hr) window during the daytime, ending by 8:00pm. Subjects will text the time of their first and last daily calorie intake for the duration of the study.
Study Locations (1 sites)
University of Kentucky Barnstable Brown Diabetes Center, Lexington, Kentucky 40504 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Type 2 Diabetes Exclusion Criteria: * Pregnant or breastfeeding * Diagnosed eating disorder * Night shift worker * Taking drugs which induce hypoglycemia * Unable or unwilling to participate in the time-restricted eating intervention
Conditions Type 1 Diabetes Mellitus, Type 2 Diabete...
Phase NA
Enrollment 270
Locations 19 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-21
Study Details Design, interventions, and primary outcomes

About This Study

This is an open label, two-arm, randomized multi-center clinical device study in adult subjects with Type 1 diabetes (T1D) or insulin-dependent Type 2 diabetes (T2D) on a multiple daily injection (MDI) regime. The goal of the study is to investigate the impact of the Accu-Chek SmartGuide CGM solution on the change in overall time in range (TIR) of blood glucose concentrations of 70-180 mg/dl compared with that using self-monitoring of blood glucose (SMBG).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: Accu-Chek SmartGuide CGM Solution — The Accu-Chek SmartGuide CGM solution is used for real-time continuous glucose monitoring (CGM) in the interstitial fluid. It consists of the Accu-Chek SmartGuide device and two smartphone applications (apps): the Accu-Chek SmartGuide app and the Accu-Chek SmartGuide Predict app. The Accu-Chek SmartGuide device contains a CGM sensor pre-assembled in a sensor applicator. It has connectivity to the smartphone that is running the Accu-Chek apps. The Accu-Chek SmartGuide app is the primary display of the real-time glucose values. The Accu-Chek SmartGuide Predict app is an information management tool that further visualizes and analyzes diabetes data from the Accu-Chek SmartGuide device.
  • Device: Accu-Chek SmartGuide Sensor and Blinded Apps — The participants in the SMBG control group will wear a SmartGuide sensor with blinded SmartGuide apps intermittently, i.e., during the assessment periods. It is not possible to read out the glucose data from the blinded app, hence neither the SmartGuide app nor the SmartGuide Predict functionalities can be accessed by the participants in this group.
  • Device: SMBG Device — With the SmartGuide apps in blinded mode, participants in the SMBG control group will continue using their own SMBG device or they may use the Accu-Chek Instant meter that will be provided for calibration of the SmartGuide device.

Primary Outcomes

  • Change in the Percentage of Time in Range of a Blood Glucose Concentration of 70 to 180 mg/dL from the Baseline Period to Assessment Period A (Baseline Period (Weeks 1 and 2) and Assessment Period A (Weeks 5 and 6))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-14
Completion: 2027-05-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 270 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hoffmann-La Roche
Collaborators: Roche Diabetes Care
Principal Investigators:
  • Clinical Trials (STUDY_DIRECTOR) - Hoffmann-La Roche
Contact Information
Study Contact:
Study ID Reference: DC000129 Roche Diabetes Care Poland and Turkey
+48 22 481 55 00; 08002113636
polska.diabetologia@roche.com; diyabetevi.turkey@roche.com
Interventions
  • Device: Accu-Chek SmartGuide CGM Solution — The Accu-Chek SmartGuide CGM solution is used for real-time continuous glucose monitoring (CGM) in the interstitial fluid. It consists of the Accu-Chek SmartGuide device and two smartphone applications (apps): the Accu-Chek SmartGuide app and the Accu-Chek SmartGuide Predict app. The Accu-Chek SmartGuide device contains a CGM sensor pre-assembled in a sensor applicator. It has connectivity to the smartphone that is running the Accu-Chek apps. The Accu-Chek SmartGuide app is the primary display of the real-time glucose values. The Accu-Chek SmartGuide Predict app is an information management tool that further visualizes and analyzes diabetes data from the Accu-Chek SmartGuide device.
  • Device: Accu-Chek SmartGuide Sensor and Blinded Apps — The participants in the SMBG control group will wear a SmartGuide sensor with blinded SmartGuide apps intermittently, i.e., during the assessment periods. It is not possible to read out the glucose data from the blinded app, hence neither the SmartGuide app nor the SmartGuide Predict functionalities can be accessed by the participants in this group.
  • Device: SMBG Device — With the SmartGuide apps in blinded mode, participants in the SMBG control group will continue using their own SMBG device or they may use the Accu-Chek Instant meter that will be provided for calibration of the SmartGuide device.
Study Locations (19 sites)
Centrum Badań Klinicznych PI-House sp. z o.o., Gdansk, 80-546 Poland
Diabetes Technology Center, Jagiellonian University Medical College, Krakow, 31-501 Poland
NZOZ Neuromed, Kraśnik, 23-204 Poland
NZOZ Neuromed, Lublin, 20-064 Poland
Institute of Rural Health, Lublin, 20-090 Poland
KO-MED Centra Kliniczne Lublin II, Lublin, 30-362 Poland
BioResearch Group Sp. z o. o., Nadarzyn, 05-830 Poland
Nbr Polska, Warsaw, 00-710 Poland
Clinic of Internal Diseases, Endocrinology and Diabetology State Medical Institute MSWiA, Warsaw, 02-507 Poland
ETG Warszawa, Warsaw, 02-677 Poland
Eligibility Criteria
Inclusion Criteria: * Type 1 Diabetes mellitus (T1D) or Type 2 Diabetes mellitus (T2D) diagnosed at least 12 months prior to screening, using multiple daily injection (MDI) regime for at least six months prior to screening * Performing SMBG, no CGM/flash glucose monitoring (FGM) use during the last six months prior screening * HbA1c ≥8% and ≤10% based on analysis from a local laboratory Exclusion Criteria: * Untreated adrenal or thyroid insufficiency * Severe visual impairment * Significant renal impairment: eGFR \<30 ml/min within last one year * Serious acute or chronic concomitant disease or an anamnesis which might, in the opinion of the investigator, pose a risk to the subject * Hematocrit greater than 10% below the lower limit of normal * Pregnancy (lack of negative pregnancy test - except in case of menopause, sterilization or hysterectomy - self-reported), planned pregnancy, or breast feeding * Allergic to the adhesive (glue or tape) * Skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) at the sensor application sites * Sickle cell disease, or hemoglobinopathy * Elective surgery planned that requires general anesthesia during study participation * Current or anticipated acute uses of glucocorticoids (oral, injectable, or intravenous) * Medical conditions that, per investigator determination, make it inappropriate or unsafe to target an HbA1c of \<7%. Conditions may include but are not limited to: heart failure, unstable cardiovascular disease, recent myocardial infarction, ventricular rhythm disturbances, recent transient ischemic attack or cerebrovascular accident, significant malignancy * Chronic use of opiates, opioids, morphinomimetics more than three times per week, which has not stopped at least 30 days prior to screening and any other medication interfering with the assessment of pain, as per investigator's discretion * Intake of hydroxyurea (hydroxycarbamide), levodopa, methyldopa, ascorbic acid, acetylsalicylic acid (≥300mg), which has not stopped at least 30 days prior to screening * Magnetic resonance tomography (MRT), computed tomography (CT), X-ray, radiofrequency ablation, high-frequency electrical heat or high intensity focused ultrasound planned during the course of the study * Planned flight or high-altitude hike (\>3000 m) during baseline and assessment periods * Shift-worker (night-shifts) * On or planning to start a diet intended for weight change * Currently abusing illicit and/or prescription drugs or alcohol as judged by the investigator * Any other physical or psychological disease or psychiatric disorder that could limit adherence to the required study tasks and interfere with the normal conduct of the study as judged by the investigator * Dependency (e.g., employee, co-worker or family member) on sponsor, investigator or companies active in the field of CGM (e.g. Dexcom, Abbott, Menarini, Medtronic) or their subsidiaries * Participation in another clinical study at the same time
Conditions Bronchial Asthma
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Asthma is considered the most common chronic childhood disease and mainly affects children resident in urban areas. Asthma has been designated a serious public health problem due to the increase in its prevalence over the last two decades and the associated high health service costs in admissions and hospitalizations The cause of asthma is not yet completely understood, and there is no consensus about its etiology. A vast body of research emphasizes the role of genetic and environmental factors in the appearance of asthma, and a great deal of interest has recently emerged concerning the relationship between psychosocial factors and asthma morbidity Behavioural problems in children are generally described as "internalizing", which includes "anxiety, depressive, and somatic symptoms" or "externalizing", which includes "oppositional, hyperactive conduct". Both internalizing and externalizing problems can be experienced by healthy children with abnormal and "borderline" personality disorder, the latter referring to a mental illness marked by an ongoing pattern of varying moods, self-image, and behaviour

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: psychometry — ADHD test and measurement of IQ level

Primary Outcomes

  • Behavioural changes among asthmatic children (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-07-15
Completion: 2025-07-15
Eligibility
Age: 4 Years – 12 Years
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sohag University
Contact Information
Study Contact:
Aya E Abd elmegaly, resident
01112487834
ayah.ezeldeen@med.sohag.edu.eg
Magdy M Amin, professor
Sohag university Hospital
Interventions
  • Diagnostic Test: psychometry — ADHD test and measurement of IQ level
Study Locations (1 sites)
Sohag university Hospital, Sohag, Egypt
Eligibility Criteria
Inclusion Criteria: Children aged 4-12 years Confirmed diagnosed as asthma Exclusion Criteria: Children below age of 4 years and aboveage of 12 years . Diagnosed with any other chronic medical conditions (e.g., cardiac , liver , renal and other chronic chest diseases) . Patient with cerebral palsy.
Conditions Asthma
Phase PHASE4
Enrollment 644
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with a BDP/FF/GB 100/6/12.5 µg on asthma control outcomes relative to ICS/LABA therapy with BDP/FF 200/6 μg in a population with asthma poorly controlled.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation) — Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide BDP/FF/GB (100/6/12.5 µg per actuation) administered via pressurised metered-dose inhaler (pMDI) 2 inhalations bid (i.e. 2 inhalations in the morning and 2 inhalations in the evening) for a total of 12 months.
  • Drug: Foster® 200/6 pMDI (BDP/FF-200/6 µg) — Beclometasone dipropionate, formoterol fumarate (BDP/FF-200/6 µg) administered via pressurised metered-dose inhaler (pMDI) 2 inhalations bid (i.e. 2 inhalations in the morning and 2 inhalations in the evening) for a total of 12 months.

Primary Outcomes

  • Change in ACQ-5 score (Baseline to Month 12 (Visit 7))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-06-28
Completion: 2028-06-13
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 644 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chiesi Farmaceutici S.p.A.
Contact Information
Study Contact:
Clinical Trial INFO Chiesi Farmaceutici S.p.A.
+39 0521 2791
clinicaltrials_info@chiesi.com
Nikolay Evgeniev Nikolaev
Medical Center Hermes Ruse LTD 12 Chavdar Voyvoda St.
Interventions
  • Drug: Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation) — Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide BDP/FF/GB (100/6/12.5 µg per actuation) administered via pressurised metered-dose inhaler (pMDI) 2 inhalations bid (i.e. 2 inhalations in the morning and 2 inhalations in the evening) for a total of 12 months.
  • Drug: Foster® 200/6 pMDI (BDP/FF-200/6 µg) — Beclometasone dipropionate, formoterol fumarate (BDP/FF-200/6 µg) administered via pressurised metered-dose inhaler (pMDI) 2 inhalations bid (i.e. 2 inhalations in the morning and 2 inhalations in the evening) for a total of 12 months.
Study Locations (1 sites)
Medical Center Hermes Ruse LTD 12 Chavdar Voyvoda St., Rousse, 7002 Bulgaria
Eligibility Criteria
Inclusion Criteria: 1 . Study participant's written informed consent obtained prior to any study related procedure. 2\. Male or female study participants aged ≥18 years old. 3. Physician confirmed documented asthma diagnosis as per current clinical practice. 4\. Stable asthma treatment prior randomisation: At least 3 months on any medium strength (MS) ICS/LABA regular treatment. 5\. Poor asthma control at randomisation (ACQ-5 ≥1.5 and at least 1 exacerbation in the previous year). 6\. Women with childbearing potential (WOCBP) and with fertile male partners: they and/or their partner must be willing to use a highly effective birth control method from the signature of the informed consent and until the last visit. 7\. Study participants must have a cooperative attitude and the ability to be trained to use the patient app correctly, to be able to perform the required outcomes measurements (e.g. ePRO completion) and the ability to understand the risks involved. Note: Study participants with asthma diagnosis and no clinically relevant concurrent COPD diagnosis upon clinical judgement can be included. Study participants on maintenance and reliever therapy (MART) can be included if the ICS dosage does not exceed 400 µg/day of beclometasone or equivalent. Exclusion Criteria: The presence of any of the following will exclude a study participant from study enrolment: 1. Participation in another interventional clinical trial. 2. Pregnant or breastfeeding women at the moment of enrolment. 3. Other chronic respiratory disease: Lung Cancer, known alpha1-antitrypsin deficiency, active tuberculosis, clinically significant bronchiectasis, interstitial lung disease, pulmonary hypertension, or any other uncontrolled/clinically significant diseases (according to investigator's judgement). 4. Contraindication for LAMA use. 5. Study participants on biological therapies for asthma. 6. For France only: Individuals under court protection (including protected adults) and individuals not affiliated to a social security system are excluded from participation in this study (Country/Region-Specific Differences - France), in accordance with Articles L.1121-6, L.1121-8, and L.1121-8-1 of the French Public Health Code.
Conditions Moderate Asthma Exacerbation, Severe Ast...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Acute exacerbation of asthma represents an acute or sub-acute worsening in symptoms and lung function in patients with asthma. It is characterized by a progressive increase in symptoms of shortness of breath, cough, wheezing, or chest tightness. It is a common diagnosis in patients admitted in an Emergency Department for dyspnoea. Near 10 to 15% of respiratory symptoms in an ED are related to acute exacerbation of asthma. Treatment of acute exacerbation of asthma associates nebulized beta-2 agonist adrenergic with or without ipratropium bromide, oral corticosteroids and controlled oxygen therapy to maintain SpO2 between 93 and 95%. Treatment in the ED did not vary during last years, including for patients with a lack of efficacy after first line treatment, and exacerbation are always associated with a hospitalisation in 40% of adult patients and with mortality in 1% of hospitalized patients. Vibrating mesh nebulizers are devices using vibration to push drug through the mesh, resulting in the drug nebulization. Vibrating mesh nebulizers have been associated with better pulmonary drug delivery than jet-nebulizers, provide faster improvement in peak expiratory flow and have been associated in retrospective studies with patient prognosis, particularly in terms of throughput time and need for hospitalisation. However, no studies have prospectively compared nebulisation with a vibrating membrane device with standard nebulisation in patients with asthma exacerbation on clinically relevant criteria. Nebulisation with a vibrating membrane device may potentiate the clinical efficacy of short-acting bronchodilators, result in faster and more effective clinical improvement, and be associated with improved short- and medium-term patient outcomes. High-flow nasal cannula heated, and humidified oxygen (HNFO) is a ventilatory support which is commonly used for the management of acute respiratory failure for acute respiratory failure in intensive care units and in emergency departments. HFNO delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF. Consequently, HFNO is associated with a decrease in the work of breathing. During asthma exacerbation, HFNO was associated with an improvement in the dyspnea level and in the respiratory rate compared with conventional oxygen therapy. However, HFNO has never been assessed in association with nebulized beta-2 adrenergic agonist. To resume, beta-2 adrenergic agonist nebulization with a vibrating mesh nebulizer seems effective, especially compared to standard jet nebulization. In addition, HFNO is a technique that appears to be suitable for the pathophysiological conditions of chronic reversible respiratory failure, and can be used during exacerbations of asthmatic disease. The high flow rate of gas makes it possible to control the…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Standard Nebulization — Beta-2 adrenergic agonist administred by standrad nebulization
  • Device: A - Vibrating mesh nebulization — Beta-2 adrenergic agonist nebulisation using a vibrating mesh nebuliser device (Aerogen, Galway, Ireland). Nebulisation will take place under medical air at 6L/min or medical O2 at 6L/min depending on the patient's needs and for a SpO2 target between 94-96%
  • Device: B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen — High-flow nasal cannula heated and humidified oxygen (HFNO) and nebulisation of beta-adrenergic agonist using a vibrating mesh device. HFNO will be administered using an Airvo2 device and beta-2 adrenergic agonist nebulisation enabled by the use of a dedicated heated humidifier and an adaptable vibrating mesh nebuliser device

Primary Outcomes

  • Number of responding patients one hour after inclusion (1 hour)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-19
Completion: 2028-03-19
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Poitiers University Hospital
Principal Investigators:
  • Nicolas MARJANOVIC, MD PHD (PRINCIPAL_INVESTIGATOR) - CHU Poitiers
Contact Information
Study Contact:
Nicolas MARJANOVIC, MD PHD
0549441873
nicolas.marjanovic@chu-poitiers.fr
Sabrina SEGUIN, CRA
0549443229
sabrina.seguin@chu-poitiers.fr
Nicolas MARJANOVIC, MD PHD
0549441873
nicolas.marjanovic@chu-poitiers.fr
University Hospital of Poitiers
Interventions
  • Device: Standard Nebulization — Beta-2 adrenergic agonist administred by standrad nebulization
  • Device: A - Vibrating mesh nebulization — Beta-2 adrenergic agonist nebulisation using a vibrating mesh nebuliser device (Aerogen, Galway, Ireland). Nebulisation will take place under medical air at 6L/min or medical O2 at 6L/min depending on the patient's needs and for a SpO2 target between 94-96%
  • Device: B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen — High-flow nasal cannula heated and humidified oxygen (HFNO) and nebulisation of beta-adrenergic agonist using a vibrating mesh device. HFNO will be administered using an Airvo2 device and beta-2 adrenergic agonist nebulisation enabled by the use of a dedicated heated humidifier and an adaptable vibrating mesh nebuliser device
Study Locations (1 sites)
University Hospital of Poitiers, Poitiers, France 86021 France
Eligibility Criteria
Inclusion Criteria: * Age equal or over 18 years * admitted in an Emergency Department with a clinical suspicion of acute exacerbation of asthma according to the Global Initiative for Asthma (GINA) criteria. * with at least one of the following criteria 60mn after a first treatment by beta-2 agonist adrenergic nebulization with 3 x 5 mg of terbutaline: * Respiratory rate over 22 breaths/min * Peak flow \< 50% of predictive normal value * SpO2 \< 95% in room air * Signs of severe asthma exacerbation (at least one criteria): Talks in word, Agitation, Sits hunched forwards, Accessory muscles in use * Free subject, without guardianship or curatorship or subordination * Patients benefiting from a Social Security scheme or benefiting from it through a third party * Informed consent signed by the patient after clear and honest information about the study Exclusion Criteria: * Acute exacerbation of asthma during the last 30 days * Clinical suspicion of acute exacerbation of asthma due to anaphylaxis, pneumothorax, pneumomediastinum, pneumonia or atelectasis. * At least ONE of the following serious signs: drowsiness, confusion, auscultatory silence * Clinical suspicion of another pathology that could explain the respiratory failure such as heart failure, laryngeal obstruction, pulmonary embolism, etc * Patients with neurological (Glasgow \< 13) or hemodynamical failure (Mean Arterial Pressure \< 65 mmHg) * contraindication to treatment with a beta-2-adrenergic agonist * History of hypersensitivity (allergy) to terbutaline or any of the constituents * Contraindication to OHD * Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, people assessed GIR1 or GIR 2 (AGGIR grid), adults under legal protection * Pregnant or breastfeeding women, Women at age to procreate and not using effective contraception
Conditions Neuropathic Pain, Anxiety Disorder/Anxie...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

Head and neck cancers are a source of complications and after-effects related to the disease and treatment. These cancers and their treatment alter the quality of life of patients and generate pain with physical and psychological components. Chronic pain affects 36% of patients at 6 months and 30% after this period. These pains are responsible for the consumption of level II and III analgesics in 53% of these patients. At the same time, after the end of treatment, nearly a quarter of patients continued to smoke and half still consumed alcohol at least twice a week. The hypothesis of this research is to investigate the correlation between pain and the continuation of addictions, the occurrence of depressive states, asthenia and the alteration of the patients' global quality of life. The investigators propose a two-center prospective cohort study to evaluate this hypothesis at 6 months after radiotherapy treatment. This study is planned to include 120 patients with a first head and neck cancer whit radiotherapy as part of their treatment sequence. The expected duration of inclusion is 18 months. The identification of factors affecting survival, quality of life and patient compliance is essential to determine appropriate management, particularly by creating appropriate therapeutic education programs.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Questionnaire — Self-questionnaires are completed by the patient at the time of this consultation: * Neuropathic pain: NPSI in screening * Anxiety/depression: HADS in screening * Quality of life: EORTC (QLQC30 and H\&N43) * Fatigue: MFI-20 hese self-questionnaires will be retrieved by the Clinical Research Associate (CRA) for verification. Depending on the result of the NPSI questionnaire can be completed to better characterize neuropathic pain. Depending on the result of the HADS, the MADRS questionnaire can be completed to quantify the degree of depression. Individuals diagnosed with neuropathic pain or other depressive symptoms during the 6-month inclusion period will be referred to and managed by specialized practitioners. This assistance will be indicated in follow-up report

Primary Outcomes

  • change, neuropathic pain 1 (Day 0", "Month 6")
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-13
Completion: 2026-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Caen
Collaborators: Centre Francois Baclesse
Principal Investigators:
  • maxime humbert, MD (PRINCIPAL_INVESTIGATOR) - University Hospital, Caen
Contact Information
Study Contact:
Maxime Humbert, MD
0231064640
humbert-m@chu-caen.fr
Emmanuel Babin, PHD
0231064640
babin-e@chu-caen.fr
Interventions
  • Other: Questionnaire — Self-questionnaires are completed by the patient at the time of this consultation: * Neuropathic pain: NPSI in screening * Anxiety/depression: HADS in screening * Quality of life: EORTC (QLQC30 and H\&N43) * Fatigue: MFI-20 hese self-questionnaires will be retrieved by the Clinical Research Associate (CRA) for verification. Depending on the result of the NPSI questionnaire can be completed to better characterize neuropathic pain. Depending on the result of the HADS, the MADRS questionnaire can be completed to quantify the degree of depression. Individuals diagnosed with neuropathic pain or other depressive symptoms during the 6-month inclusion period will be referred to and managed by specialized practitioners. This assistance will be indicated in follow-up report
Study Locations (1 sites)
Caen University Hospital, Caen, France
Eligibility Criteria
Inclusion Criteria: * Patients with a first Head and neck cancer whose therapeutic sequence involves radiotherapy * Patient over 18 years of age * Having given written consent * patient not previously treated with radiotherapy * Life expectancy \> 3 months * World Health Organization (WHO) score \< 3 * Histologically proven Head and Neck cancer * Stable patient, with no signs of recurrence or other progressive neoplasia at the time of the examination * Patient treated with radiotherapy * Patient fluent in French Exclusion Criteria: * Non-consenting patient * History of malignancy, other than treated and cured basal cell or cervical cancer * Patient who has had a salvage surgery other than lymph node removal * Patient with evidence of recurrence or other progressive neoplasia at the time of examination * Patient who has had previous mutilating surgery (causing sequelae of swallowing and eating) * Uncontrolled infectious pathology * Patient under 18 years of age * Patient who is not fluent in French * Patient with a psychiatric pathology that could disrupt the study or prevent the interpretation of the results.

The Role of mGluR5 in CBT-I

NCT07076342
Recruiting
Conditions Major Depressive Disorder (MDD)
Phase PHASE4
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Cognitive Behavioral Therapy for Insomnia — Cognitive Behavioral Therapy for Insomnia (CBT-I) will be delivered through an online program, Sleep Healthy Using The Internet Sleep Healthy Using The Internet (SHUTi)
  • Drug: PET Scan with [11C]ABP688 — Prior to and after completing the CBT-I protocol, participants will undergo a PET scan using tracer \[11C\]ABP688) to quantify hippocampal mGluR5 density.

Primary Outcomes

  • Change in Sleep Latency from Baseline to 8 Weeks (Baseline and 8 Weeks)
  • Change from Baseline of mGluR5 density in the hippocampus after 8 weeks of CBT-I Treatment (Baseline and 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-08-01
Completion: 2030-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stony Brook University
Collaborators: National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Wendy Zhang
(631)-638-2053
Wendy.Zhang@stonybrookmedicine.edu
Christine DeLorenzo, PhD
(631) 638-1523
christine.delorenzo@stonybrookmedicine.edu
Christine DeLorenzo, PhD
(631) 638-1523
Christine.DeLorenzo@stonybrookmedicine.edu
Stony Brook University: Dept of Psychiatry
Interventions
  • Behavioral: Cognitive Behavioral Therapy for Insomnia — Cognitive Behavioral Therapy for Insomnia (CBT-I) will be delivered through an online program, Sleep Healthy Using The Internet Sleep Healthy Using The Internet (SHUTi)
  • Drug: PET Scan with [11C]ABP688 — Prior to and after completing the CBT-I protocol, participants will undergo a PET scan using tracer \[11C\]ABP688) to quantify hippocampal mGluR5 density.
Study Locations (1 sites)
Stony Brook University: Dept of Psychiatry, Stony Brook, New York 11794 United States
Eligibility Criteria
Inclusion Criteria: * capacity to provide informed consent, * at least 18 years of age * good physical health and absence of significant medical conditions, * diagnosis of major depressive disorder (MDD) with current major depressive episode as per DSM-5 criteria * Montgomery-Åsberg Depression Rating Scale (MADRS) score \> 29 (at least moderate depression), * uniform range of sleep latencies up to 128 minutes. Exclusion Criteria: * currently taking effective antidepressants, * lifetime history of psychosis, * drug or alcohol dependence in the last 6 months or abuse in the last 2 months * unstable medical condition (i.e., condition not adequately stabilized for ≥ 3 months) * nicotine use within 1 year * currently on medication known to affect glutamate, * sleep disorders, other than insomnia, such as sleep apnea, * recent (within 1 year) regular night shift work (or rotating shift work) or recent (within 3 months) travel across more than one time zone, or plans for this work or travel during the study period, * use of medication or substances that affect sleep, for example, ingestion of more \> 600 mg of caffeine per day, * PET or MRI contraindications, including pregnancy or currently breastfeeding
Conditions Mood Disorders, Anxiety, Depressive Symp...
Phase NA
Enrollment 150
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-20
Study Details Design, interventions, and primary outcomes

About This Study

It is envisioned that multipronged benefits from this pilot work for the UPMC ISD and its members. It is expected the RxWell platform to provide the following benefits: expansion of the use of RxWell to all UPMC ISD members providing peri-operative mood management with advantage of improved peri-operative outcomes, improving saving for the UPMC ISD by hastening the recovery and decreased resource utilization, and addition to the high-value care of UPMC with this holistic approach to patient perioperative care

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: +RxWell — During the SuRxgWell trial, if a participant is randomized to receive RxWell, they will be provided with an access code that is required to download the app. Once the participant has downloaded the app, they will be paired with a UPMC coach who will guide the person through the sessions using in-app texting to help give them the tools needed to actively cope with anxiety and/or depression. The UPMC coaches are supervised by a licensed UPMC mental health clinician. The participant will have access to the app and coach for six months after they have consented. The digital behavioral tool includes over 30 brief Cognitive Behavioral Therapy (CBT) and mindfulness-based techniques. Subjects enrolled after 01DEC25 were unable to download the RxWell application because it was removed from the app store. To avoid disruption, direct access to the RxWell application was replaced with a 30-minute, directed, telemedicine, health coaching session, on at least 2 occasions prior to surgery.
  • Behavioral: -RxWell — Treatment as usual

Primary Outcomes

  • Cumulative Opioid Consumption in Oral Morphine Equivalent (OME) (mg) (POD 1 to Week 4 Post-Op)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-01-27
Completion: 2026-12-30
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Principal Investigators:
  • Ata Murat Kaynar, MD, MPH (PRINCIPAL_INVESTIGATOR) - UPMC Department of Anesthesiology and Perioperative Medicine
Contact Information
Study Contact:
Ata Murat Kaynar, MD, MPH
412-383-3463
kaynarm@upmc.edu
Carly Riedmann, MPH
412-623-4147
riedmannca@upmc.edu
Ata Murat Kaynar, MD, MPH
412-383-3463
kaynarm@upmc.edu
UPMC East
Interventions
  • Behavioral: +RxWell — During the SuRxgWell trial, if a participant is randomized to receive RxWell, they will be provided with an access code that is required to download the app. Once the participant has downloaded the app, they will be paired with a UPMC coach who will guide the person through the sessions using in-app texting to help give them the tools needed to actively cope with anxiety and/or depression. The UPMC coaches are supervised by a licensed UPMC mental health clinician. The participant will have access to the app and coach for six months after they have consented. The digital behavioral tool includes over 30 brief Cognitive Behavioral Therapy (CBT) and mindfulness-based techniques. Subjects enrolled after 01DEC25 were unable to download the RxWell application because it was removed from the app store. To avoid disruption, direct access to the RxWell application was replaced with a 30-minute, directed, telemedicine, health coaching session, on at least 2 occasions prior to surgery.
  • Behavioral: -RxWell — Treatment as usual
Study Locations (3 sites)
UPMC East, Monroeville, Pennsylvania 15146 United States
UPMC Shadyside, Pittsburgh, Pennsylvania 15232 United States
UPMC Passavant, Pittsburgh, Pennsylvania 15237 United States
Eligibility Criteria
Inclusion Criteria for the RXWell Study: * Adults \>18 years * Scheduled for elective primary total knee arthroplasty (TKA) or hip replacement (THA) at the approved UPMC hospitals * Moderately high levels of mood disorder symptoms on validated PROMIS measures, defined as a T-score \> or = to 60 on PROMIS Anxiety 4a short form and/or PROMIS Depression4a short form Exclusion Criteria for the RXWell Study: * Patients undergoing non-elective surgery or secondary arthroplasty * Active delirium, neurocognitive impairment, or severe intellectual disability * No access to a smart device (phone or tablet) * Active alcoholism (defined as daily use of more than 1 liter of wine and /or 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs) * Profound mood disorders requiring immediate intervention such as suicidal ideation, defined as a PROMIS Depression score of more than 70 * A PROMIS Anxiety and/or Depression T-score \>70, which corresponds to severe anxiety and depression. * Patients needing immediate care will be referred to psychiatrists and primary team.